Sugi Predict

Sugi Predict / Compounds / SCHEMBL871995

SCHEMBL871995

SCHEMBL871995

Cc1ccc2nc(C=O)cn2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 13/20 0.50
▸ RAB9A P51151 12/20 0.50
▸ ALDH1A1 P00352 11/20 0.50
▸ KDM4E B2RXH2 10/20 0.50
▸ SMN1; SMN2 Q16637 7/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ PAX8 Q06710 2/20 0.50
▸ MITF O75030 1/20 0.50
▸ KDM5A P29375 1/20 0.50
▸ KDM5C P41229 1/20 0.50
▸ HPGD P15428 6/20 0.46
▸ PKM P14618 4/20 0.46
▸ TP53 P04637 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ APP P05067 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784975 0.79 RAB9A (0.51) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL14046264 0.79 PIK3CG (0.38) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL869867 0.79 APP (0.43) NPC1RAB9AALDH1A1KDM4EAPP
SCHEMBL5773449 0.79 APP (0.43) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL11914801 0.79 PIK3CG (0.55) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL31035678 0.78 PTGS2 (0.45) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL21033713 0.77 ALDH1A3 (0.39) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL4885799 0.77 SMN1; SMN2 (0.53) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL25283922 0.76 NPC1 (0.46) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL31035779 0.76 ROCK1 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 — — US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 — — US disclosed
CN-118434744-A Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof 中国医药研究开发中心有限公司 2024-08-02 — — CN disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 — — US disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 — — US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 — — US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 — — US disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 — — EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 — — CN disclosed
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors ALCON RESEARCH, LTD. 2010-08-12 — — US disclosed
EP-2106396-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS AstraZeneca AB (SE) 2009-10-07 — — EP disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 — — US disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 — — US disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 — — US disclosed
US-20080171740-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-07-17 — — US disclosed
WO-2008084223-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS ASTRAZENECA AB (SE) 2008-07-17 — — WO disclosed
WO-2008084223-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS ASTRAZENECA AB (SE) 2008-07-17 — — WO disclosed
EP-1793825-A2 CHEMCIAL COMPOUNDS SmithKline Beecham Corporation (US) 2007-06-13 — — EP disclosed
WO-2006036816-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 NPC1 2030/4885RAB9A 1839/4885ALDH1A1 1264/4885
US-20080171740-A1 Chemical Compounds CXCR4, CCR5, CXCR3 NPC1 187/4885RAB9A 1507/4885ALDH1A1 2769/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 NPC1 952/4885RAB9A 776/4885ALDH1A1 4277/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 NPC1 2467/4885RAB9A 2887/4885ALDH1A1 2556/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT NPC1 418/4885RAB9A 1986/4885ALDH1A1 1727/4885
US-20090124596-A1 Chemical Compounds 637 PDE4A, PDE4B, PDE3B NPC1 2462/4885RAB9A 1736/4885ALDH1A1 331/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 NPC1 952/4885RAB9A 776/4885ALDH1A1 4277/4885
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors PDE4A, PDE4B, PDE5A NPC1 3510/4885RAB9A 1730/4885ALDH1A1 295/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 NPC1 2030/4885RAB9A 1839/4885ALDH1A1 1264/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 NPC1 952/4885RAB9A 776/4885ALDH1A1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.